During TB treatment, pyrazinamide is given concomitantly (or even co-formulated) with rifampicin, which is a well-known potent inducer of hepatic and intestinal CYP3A subfamily and many other metabolic pathways via activation of the pregnane X-receptor (PXR) [39]. The gene discussed is NR1I2; the disease is tuberculosis.